GSK Offers a Window Into Attempts at Biotech-like R&D

During a nearly two-hour R&D seminar, executives at GlaxoSmithKline PLC described the company's evolving strategy, detailing the organization's goals, capital allocation, and productivity performance, and providing a glimpse into the ongoing work within six of its 40 biotech-like discovery performance units.